Salivary antipyrine half-life during injectable progestagen contraception.
Antipyrine pharmacokinetics were studied in 6 healthy women before and 2, 8 and 12 weeks after administering the injectable progestagen (progestin), norethisterone (norethindrone) enanthate 200mg intramuscularly. Additionally, antipyrine kinetics in 5 women who had previously used the injectable contraceptive for 8 to 14 months were compared with values obtained in 14 non-users. Antipyrine was measured in saliva using a spectrophotometric method, following an oral dose of 18 mg/kg bodyweight. In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection. The mean antipyrine half-life in the 5 long term users of injectable progestagen was 14.21 +/- 2.53 hours compared with 13.66 +/- 0.98 hours in non-users. The results of this study suggest that - in contrast to published data on combined oral contraceptives - neither short nor long term use of parenteral norethisterone enanthate in Indian women is associated with significant alterations in antipyrine clearance.
D000328:Adult; D000983:Antipyrine / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007273:Injections, Intramuscular; D007700:Kinetics; D009640:Norethindrone / Q000031:analogs & derivatives* / Q000494:pharmacology; D011446:Prospective Studies; D012463:Saliva / Q000378:metabolism*
C024319:norethindrone enanthate; D009640:Norethindrone; D000983:Antipyrine